[go: up one dir, main page]

MX2017009153A - Proteinas de fusion de citoquinas. - Google Patents

Proteinas de fusion de citoquinas.

Info

Publication number
MX2017009153A
MX2017009153A MX2017009153A MX2017009153A MX2017009153A MX 2017009153 A MX2017009153 A MX 2017009153A MX 2017009153 A MX2017009153 A MX 2017009153A MX 2017009153 A MX2017009153 A MX 2017009153A MX 2017009153 A MX2017009153 A MX 2017009153A
Authority
MX
Mexico
Prior art keywords
fusion proteins
cytokine fusion
cytokin
nucleic acid
acid molecules
Prior art date
Application number
MX2017009153A
Other languages
English (en)
Other versions
MX385926B (es
Inventor
Sahin Ugur
Kreiter Sebastian
GIESEKE Friederike
Backer Ronald
Kontermann Roland
Pfizenmaier Klaus
FELLERMAIER Sina
MÜLLER Dafne
Original Assignee
Univ Stuttgart
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Stuttgart filed Critical Univ Stuttgart
Publication of MX2017009153A publication Critical patent/MX2017009153A/es
Publication of MX385926B publication Critical patent/MX385926B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se relaciona a proteínas de fusión de citoquinas y a moléculas de ácido nucleico que codifican dichas proteínas de fusión de citoquinas. La presente invención además se relaciona a las células, organismos no humanos, composiciones farmacéuticas y kits que incluyen proteínas de fusión de citoquinas o las moléculas de ácido nucleico que las codifican, así como a su utilización como medicamentos.
MX2017009153A 2015-01-15 2016-01-15 Proteínas de fusión de citoquinas. MX385926B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2015/050682 WO2016112983A1 (en) 2015-01-15 2015-01-15 Cytokine fusion proteins
PCT/EP2016/050773 WO2016113395A1 (en) 2015-01-15 2016-01-15 Cytokine fusion proteins

Publications (2)

Publication Number Publication Date
MX2017009153A true MX2017009153A (es) 2018-02-01
MX385926B MX385926B (es) 2025-03-18

Family

ID=52394237

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017009153A MX385926B (es) 2015-01-15 2016-01-15 Proteínas de fusión de citoquinas.
MX2021010668A MX2021010668A (es) 2015-01-15 2017-07-12 Proteinas de fusion de citoquinas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021010668A MX2021010668A (es) 2015-01-15 2017-07-12 Proteinas de fusion de citoquinas.

Country Status (11)

Country Link
US (2) US10301368B2 (es)
EP (1) EP3245223B1 (es)
JP (1) JP6813491B2 (es)
CN (2) CN107428842B (es)
AU (1) AU2016207955B2 (es)
BR (1) BR112017013956B1 (es)
CA (1) CA2971950C (es)
HK (1) HK1246316A1 (es)
MX (2) MX385926B (es)
NZ (1) NZ733266A (es)
WO (2) WO2016112983A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013156054A1 (en) * 2012-04-16 2013-10-24 Universität Stuttgart The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity
MA41460A (fr) 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
WO2018027025A1 (en) * 2016-08-03 2018-02-08 Oncomed Pharmaceuticals, Inc. Cd40-binding agents and uses thereof
US12161668B2 (en) 2017-01-10 2024-12-10 The General Hospital Corporation T cells expressing a chimeric antigen receptor
MY207687A (en) * 2017-02-27 2025-03-12 Shattuck Labs Inc Tigit- and light-based chimeric proteins
UY37621A (es) 2017-02-28 2018-09-28 Sanofi Sa Arn terapéutico que codifica citoquinas
EP3606949A1 (en) 2017-04-06 2020-02-12 Universität Stuttgart Tumor necrosis factor receptor (tnfr) binding protein complex with improved binding and bioactivity
US11377490B2 (en) * 2017-05-31 2022-07-05 Sichuan Clover Biopharmaceuticals, Inc Method for treating cancer using disulfide-linked trimeric 4-1BBL
US11471490B2 (en) * 2017-07-03 2022-10-18 Torque Therapeutics, Inc. T cells surface-loaded with immunostimulatory fusion molecules and uses thereof
AU2019206573B2 (en) * 2018-01-10 2024-06-06 The General Hospital Corporation Immune cells expressing a chimeric antigen receptor
US20210260165A1 (en) 2018-06-01 2021-08-26 Sanofi Combination therapy for treating hepatitis b virus infection
CA3115530A1 (en) * 2018-10-17 2020-04-23 Albert Einstein College Of Medicine Method of enhancing antibody-dependent cell-mediated cytotoxicity (adcc)
TW202515617A (zh) * 2019-01-14 2025-04-16 美商建南德克公司 用於癌症療法之rna分子
CA3140664A1 (en) 2019-06-24 2020-12-30 Roman Fischer Tnfr2 agonists with improved stability
CN112625137B (zh) * 2019-10-08 2021-10-08 北京东方百泰生物科技股份有限公司 一种人白细胞介素10-Fc融合蛋白及其医药用途
US12351618B2 (en) 2019-10-08 2025-07-08 Fred Hutchinson Cancer Center Engineered trimeric CD70 proteins and uses thereof
CA3163358A1 (en) 2019-12-03 2021-06-10 Evotec International Gmbh Interferon-associated antigen binding proteins and uses thereof
CN111018999B (zh) * 2019-12-05 2022-07-12 沣潮医药科技（上海）有限公司 二聚体免疫融合蛋白、药物组合物和用途
WO2022036495A1 (en) 2020-08-17 2022-02-24 Utc Therapeutics Inc. Lymphocytes-antigen presenting cells co-stimulators and uses thereof
CA3234897A1 (en) * 2021-10-14 2023-04-20 Kunle Odunsi Compositions and methods for use of recombinant t cell receptors against claudin 6

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19963859A1 (de) * 1999-12-30 2001-07-12 Apotech Res & Dev Ltd Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen
DE102004014983A1 (de) * 2004-03-26 2005-10-20 Univ Stuttgart Rekombinante Polypeptide der Mitglieder der TNF Ligandenfamilie und deren Verwendung
US9931386B2 (en) * 2008-06-16 2018-04-03 Atsuo Ochi Recombinant multiple domain fusion protein mitogens and use thereof for inducing enhancement or repression of antigen-specific immunity
SI2310509T1 (sl) 2008-07-21 2015-07-31 Apogenix Gmbh TNFSF enoverižne molekule
US9221895B2 (en) * 2009-03-13 2015-12-29 The Trustees Of The University Of Pennsylvania OX40/TRAIL fusion proteins
WO2013156054A1 (en) 2012-04-16 2013-10-24 Universität Stuttgart The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity
CN105309364A (zh) * 2012-04-24 2016-02-10 北欧机械制造鲁道夫巴德尔有限及两合公司 鱼积聚器
DK2970427T3 (da) * 2013-03-15 2020-03-09 Geoffrey W Stone Sammensætning bestående af antigen bundet til en tnf-superfamilieligand

Also Published As

Publication number Publication date
NZ733266A (en) 2022-04-29
EP3245223A1 (en) 2017-11-22
BR112017013956A2 (pt) 2018-01-16
HK1246315A1 (zh) 2018-09-07
CN113801241A (zh) 2021-12-17
HK1246316A1 (zh) 2018-09-07
CN107428842B (zh) 2021-10-01
MX385926B (es) 2025-03-18
JP2018503379A (ja) 2018-02-08
BR112017013956A8 (pt) 2019-04-02
CA2971950C (en) 2024-09-10
EP3245223B1 (en) 2020-03-04
US20190276511A1 (en) 2019-09-12
WO2016113395A1 (en) 2016-07-21
AU2016207955B2 (en) 2020-05-28
CN107428842A (zh) 2017-12-01
BR112017013956B8 (pt) 2024-01-23
US10301368B2 (en) 2019-05-28
AU2016207955A1 (en) 2017-07-20
JP6813491B2 (ja) 2021-01-13
WO2016112983A1 (en) 2016-07-21
CA2971950A1 (en) 2016-07-21
US10808019B2 (en) 2020-10-20
MX2021010668A (es) 2021-09-28
BR112017013956B1 (pt) 2024-01-23
US20180002392A1 (en) 2018-01-04

Similar Documents

Publication Publication Date Title
MX2017009153A (es) Proteinas de fusion de citoquinas.
AR132094A2 (es) Composiciones detergentes, variantes de lipasa y polinucleótidos que las codifican
CY1124740T1 (el) Συνθεσεις που περιλαμβανουν συνθετiκα πολυνουκλεοτιδια που κωδικοποιουν crispr σχετικες πρωτεϊνες και συνθετικα sgrnas και μεθοδοι χρησης
CO2018002196A2 (es) Proteínas de fusión de factor ix y métodos para producirlas y utilizarlas
CO2018000648A2 (es) Compuestos de piridina sustituidos, intermediarios para su preparación y composiciones que los comprenden
BR112019000195A2 (pt) composições e métodos relacionados a sistemas celulares terapêuticos que expressam rna exógeno
CL2017002820A1 (es) Variantes de alfa-amilasa y polinucleótidos que codifican las mismas
CO2018002703A2 (es) Anticuerpos anti-promiostatina o miostatina latente y usos de los mismos
CL2017002123A1 (es) Heterociclos biciclicos como inhibidores de fgnr
PE20190563A1 (es) Genes de mini-distrofina optimizados y casetes de expresion y su uso
CO2017005842A2 (es) Anticuerpos heterodiméricos que se unen a cd3 y cd38
AR101845A1 (es) Anticuerpos anti-her2 e inmunoconjugados
CY1118168T1 (el) Διπλα ειδικα αντισωματα εναντι cd3εψιλον και bcma
BR112018008051A2 (pt) vacinas de ácido nucleico para vírus de varicella zoster (vzv)
BR112016015105A2 (pt) Conjugados var2csa-droga
MX2019002842A (es) Variantes de alfa-glucosidasa acida y usos de las mismas.
MX2018010301A (es) Sales de derivados de piperazina obtenidas por adicion de acidos.
CL2019000033A1 (es) Variantes de xilanasa y polinucleótidos que las codifican.
MX2016002571A (es) Regulador de ph de transduccion.
AR095774A1 (es) Anticuerpos anti-il-4 y anticuerpos biespecíficos y sus usos
MX2014010755A (es) Moleculas de union humanas que pueden unirse a los virus de la influenza b y neutralizarlos, y sus usos.
BR112018012262A2 (pt) composições de interleucina-15 e seus usos
DOP2017000191A (es) Nuevas proteínas específicas para pioverdina y pioquelina
MX2017008817A (es) Composiciones y metodos para la glicosilacion de proteinas.
EA201790505A1 (ru) Соединение, нацеленое на ил-23а и фно-альфа, и его применение